Clinical Trial: Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07601295) titled 'Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)' on May 15.

Brief Summary: The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class II-IV pulmonary arterial hypertension (PAH).

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Pulmonary Arterial Hypertension (PAH)

Intervention: DRUG: Tiprelestat (5 mg)

5 mg of tiprelestat in 1 mL saline administered as a daily subcutaneous ...